Krystal Biotech (KRYS) drew attention after reporting second quarter 2026 results, with earnings and revenue above analyst expectations, supported by Vyjuvek sales, broad reimbursement approvals, and ongoing expansion in U.S. and international markets.

The latest Q2 earnings beat has coincided with some short term volatility in Krystal Biotech’s share price, with a 7 day share price return of down 10.83% and a 30 day share price return of down 13.41%. However, the year to date share price return of 31.53% and 1 year total shareholder return of 136.45% indicate that longer term momentum has been strong as investors reassess growth potential and risks around Vyjuvek and the broader pipeline.

If Krystal Biotech’s recent move has you looking beyond a single stock, this could be a good moment to broaden your search using the 41 healthcare AI stocks

After Krystal Biotech’s strong run over 1 year and the recent pullback following Q2 results, you face a simple decision. Lean into the current price reset or wait for an even cheaper entry as expectations cool.

Most Popular Narrative: 10.2% Undervalued

Based on the most followed narrative, Krystal Biotech’s fair value of $361.67 sits above the last close of $324.77. This frames the current debate around the stock.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product.

Favorable dynamics in global healthcare, such as greater willingness to reimburse curative, high-value genetic therapies and broadening awareness due to successful launches and patient outcomes, should support sustainable long-term revenue growth and premium pricing, boosting revenue visibility and potentially net margins.

Want to understand why this narrative sees room above today’s $324.77 share price? It focuses on compounded growth, sturdier margins, and a richer earnings mix than the past.

Result: Fair Value of $361.67 (UNDERVALUED)

However, you still need to weigh meaningful risks to this Krystal Biotech narrative, including VYJUVEK’s revenue concentration and the dependence on successful reimbursement and clinical readouts.

Another View on Krystal Biotech’s Valuation

The SWS DCF model presents a very different picture for Krystal Biotech. On this view, the stock at $324.77 sits well below an estimated future cash flow value of $1,054.32, which appears very undervalued. That is a wide gap. Which perspective do you find more credible: the DCF model or the market’s current pricing?

Next Steps

If the mix of upside and concern around Krystal Biotech feels finely balanced, quickly review the data for yourself and form a clear stance using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Krystal Biotech?

Krystal Biotech may sit at the center of your watchlist today, but widening your opportunity set can help you spot fresh ideas before the crowd notices.

• Target resilient income potential by scanning companies that feature the 7 dividend fortresses and see which payouts might suit your goals.
• Hunt for quality at a discount through the 52 high quality undervalued stocks and compare how these stocks stack up against your current holdings.
• Spot future standouts early by checking the screener containing 18 high quality undiscovered gems and avoid missing companies that others may only notice much later.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.